Interferon gamma runs interference on persistent COVID-19
Authors:
Abstract
No abstract availableKeywords
Funding Information
- G. Harold and Leila Y. Mathers Foundation
- National Institutes of Health (1K08AI128745)
- National Institutes of Health (5T32AI007517)
- National Institutes of Health (R01 AI162645)
- Pew Charitable Trusts
This publication has 11 references indexed in Scilit:
- Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?Journal of Clinical Immunology, 2021
- Immunostimulation with interferon‐γ in protracted SARS‐CoV‐2 pneumoniaJournal of Medical Virology, 2021
- Precision Medicine for COVID-19JAMA, 2021
- Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 SeverityThe Journal of Infectious Diseases, 2021
- Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019Clinical Infectious Diseases, 2021
- Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesisIntensive Care Medicine, 2021
- Immune determinants of COVID-19 disease presentation and severityNature Medicine, 2021
- Disease Tolerance as a Defense StrategyScience, 2012
- Clinical Use of Interferon‐γAnnals of the New York Academy of Sciences, 2009
- Chromosome Variability and Geographic Distribution in InsectsScience, 1966